论文部分内容阅读
目的探讨莫沙必利联合黛力新治疗功能性消化不良的临床疗效。方法选取杭州市萧山区第三人民医院2015年3月—2016年3月收治的功能性消化不良患者76例,随机分成观察组38例与对照组38例。观察组患者予以莫沙必利联合黛力新治疗,对照组患者予以莫沙必利治疗,两组患者均连续治疗4周,比较两组患者临床疗效、症状评分,观察患者不良反应发生情况。结果观察组患者临床疗效优于对照组(P<0.05)。治疗前两组患者症状评分比较,差异无统计学意义(P>0.05);治疗后观察组患者症状评分低于对照组(P<0.05)。两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论莫沙必利联合黛力新治疗功能性消化不良的临床疗效确切,可有效改善患者临床症状,且不增加不良反应发生风险。
Objective To investigate the clinical efficacy of mosapride combined with deacetylene in the treatment of functional dyspepsia. Methods 76 patients with functional dyspepsia admitted to the Third People’s Hospital of Xiaoshan District of Hangzhou from March 2015 to March 2016 were randomly divided into observation group (38 cases) and control group (38 cases). Patients in the observation group were treated with mosapride combined with Deanxit and patients in the control group were treated with mosapride. Patients in both groups were treated continuously for 4 weeks. The clinical efficacy and symptom scores of the two groups were compared and the adverse reactions were observed. Results The clinical efficacy of the observation group was better than that of the control group (P <0.05). There was no significant difference in symptom scores between the two groups before treatment (P> 0.05). After treatment, symptom score of the observation group was lower than that of the control group (P <0.05). Two groups of patients with adverse reactions, the difference was not statistically significant (P> 0.05). Conclusion Mosapride combined with Deanxit has definite curative effect in treating functional dyspepsia, which can effectively improve the clinical symptoms and does not increase the risk of adverse reactions.